Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing

Department of Rheumatology and Immunology, Peking University People's Hospital, 11 Xizhimen South St, Beijing 100044, China.
Rheumatology (Oxford, England) (Impact Factor: 4.44). 12/2011; 51(4):721-9. DOI: 10.1093/rheumatology/ker370
Source: PubMed

ABSTRACT To investigate the prevalence of eight common rheumatic diseases in a large Chinese population.
A population-based epidemiological investigation of the prevalence of eight common rheumatic diseases in a suburb of Beijing was conducted in 14 642 individuals. A community-based survey was carried out using a screening questionnaire. Positive responders were included in a clinical and laboratory examination. Diagnosis was based on the criteria of ACR or those used widely in literature.
A total of 10 556 inhabitants were interviewed. Forty-three cases of RA were identified with an age-adjusted prevalence of 0.28% (95% CI 0.19%, 0.41%). Gout was diagnosed with a crude prevalence of 0.09% (95% CI 0.05%, 0.17%). Psoriasis was reported in 28 individuals with a prevalence of 0.27% (95% CI 0.18%, 0.38%). This included two cases diagnosed with PsA, resulting in a prevalence of 7.14% (95% CI 0.88%, 23.5%) in psoriasis patients and 0.02% (95% CI 0%, 0.07%) in the general population. Three individuals were identified with SLE, with a prevalence of 0.03% (95% CI 0%, 0.06%). One individual was identified with SSc and the calculated prevalence was 0.01% (95% CI 0%, 0.05%). One case of Behçet's disease was identified, giving a prevalence of 0.01% (95% CI 0%, 0.05%).
This large-scale epidemiological survey provides an estimate of the burden of rheumatic diseases in China.

  • Rheumatology (Oxford, England) 07/2012; 51(10):1733-4. DOI:10.1093/rheumatology/kes166 · 4.44 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cutaneous lupus erythematosus (CLE) refers to those subtypes of lupus erythematosus (LE) that have predominantly skin manifestations. Discoid lupus erythematosus (DLE), subacute cutaneous lupus erythematosus (SCLE), LE panniculitis (LEP) and lupus erythematosus tumidus (LET) all fall into the category of CLE. The pathogenesis of CLE is likely multifactorial. UV irradiation has been shown to induce keratinocyte apoptosis. Impaired clearance of apoptotic cells is a potential mechanism for the development of CLE. UV irradiation can also induce externalization of autoantigens such as Ro/SSA, exposing them to circulating autoantibodies. Some drugs have been associated with CLE. Possible mechanisms include stimulation of an immune response through disruption of central tolerance and altered T cell function. T17 cells may also play a role in the pathogenesis of CLE as they have been detected in skin lesions of LE. Treg cells have been found to be decreased in LE lesions, which may contribute to the breakdown of self-tolerance. Epidermal Langerhans cells are reduced in CLE while plasmacytoid DCs are increased in the lesions of CLE, suggesting that DCs may also play an important role in the pathogenesis of CLE. Type I IFN- and TNF-α are both upregulated in lesions of CLE. Other cytokines such as IL-6 and IL-17 are also implicated in the pathogenesis of CLE. Cellular and cytokine networks can be impacted by environmental factors and genetic variations and this can result in an increased risk of developing autoimmune diseases such as CLE.
    Journal of Autoimmunity 02/2013; 41. DOI:10.1016/j.jaut.2013.01.007 · 7.02 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can be associated with permanent joint damage and disability. Because patients may be unaware of the association of joint disease with psoriasis, dermatologists play an important role in identifying PsA. In this review, we discuss the natural history and key features of PsA, the epidemiology and hypothesized risk factors for disease, and screening tools that can be used in the dermatology clinic to aid in identifying which patients should be referred to a rheumatologist for further assessment.
    03/2013; 2(1). DOI:10.1007/s13671-012-0032-8
Show more